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Puberty is a critical stage of development in an individual’s life. Puberty occurs when a child develops into an adolescent. The onset of puberty is socially and culturally 
an important milestone and an indicator of public health [1]. 
Normal puberty begins between 8 and 13 years of age in girls and 
between 9 and 14 years of age in boys [2]. Precocious puberty is 
the appearance of appropriate secondary sexual characters before 
the age of 8 years in girls and before 9 years in boys [3]. As per 
data from the west, precocious puberty currently affects 1 in 5000 
children and is 10 times more common in girls [4]. Increasing 
incidences of precocious puberty across cities and towns globally 
warrant detailed research. Majority of scientists think that the 
cause is idiopathic. Some studies have proved that secular trends 
are also the main cause of precocious puberty [5,6].
Untreated early puberty leads to early sexual maturation with 
growth and bone age advancement with early fusion, leading to 
the paradox of tall stature in childhood but short adult final height. 
Hence, it becomes important to arrest the progression of puberty 
and bring about regression of the sexual characters, increase the 
prospects for better adult height. Specific therapy could be offered 
once the underlying cause is identified. Various studies conducted 
show that factors such as obesity, consumption of junk food, lack 
of physical exercise, diet habits, low socioeconomic status, and 
education of parents have a major role in the development of 
precocious puberty [7-11].
It may be hard to diagnose precocious puberty in a child with 
minimal symptoms. Especially in girls, the diagnosis of precocious 
puberty should be confirmed by showing increase in gonadotropin 
and/or sex steroids, accelerated somatic development, and bone 
age advancement. The signs of sexual development also need to 
be regularly followed up. If the mentioned signs do not progress 
during the follow-up, then breast development can be accepted 
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as a normal variant. The objective of this study was to explore 
the precocious puberty in terms of clinical and endocrinological 
aspect.
MATERIALS AND METHODS
This was a cross-sectional observational study carried out at a 
tertiary care center over a period of 2 years. A total of 28 children 
(23 girls and 5 boys) with a history of precocity or clinical 
evidence of precocity, in boys <9 years and girls <8 years of 
age, were included. Children with a history or clinical evidence 
of precocity but not fitting into specific age group (boys above 
9 years and girls above 8 years of age) were excluded from the 
study.
The study was conducted with approval from the institutional 
ethics committee. Informed consent was taken from the parents 
before enrolled for the study. Details regarding age, gender, and 
chronology of the appearance of secondary sexual characteristics 
before the age of 8 years in a girl (B2 stage as per tanner 
staging chart) or before the age of 9 years in a boy (G2 and/or 
testicular volume 4 ml as measured by Prader’s orchidometer), 
and associated symptoms were noted. Physical examination 
was focused on quantifying puberty by Tanner staging and 
anthropometric measurements on new Indian Academy of 
Pediatrics 2015 growth charts.
Enrolled children then underwent radiological and biochemical 
investigations. Bone age assessment using Tanner-Whitehouse-3 
method provided an indication of skeletal advancement from 
excess sex steroids and was used to estimate final height since 
bone age corresponds more to sexual maturity as compared to 
chronological age. Ultrasound of abdomen and pelvis was done to 
see uterine size and shape, endometrial thickness, fundocervical 
ratio, ovarian size, and volume. Magnetic resonance imaging 
(MRI) of the brain was done in all boys with central precocious 
puberty (CPP), given the high prevalence of organic causes in 
this group as well as in girls <6 years. Thyroid function tests were 
done to rule out hypothyroidism.
The key endocrine investigation was to determine the 
luteinizing hormone (LH) and follicle-stimulating hormone 
(FSH) response to acute gonadotropin-releasing hormone (GnRH) 
stimulation to distinguish between central and non-central 
(peripheral) forms of precocious puberty. GnRH stimulation test 
is an important tool in the valuation of children with precocious 
puberty. The test was performed by measurement of LH and FSH 
at baseline and 20 and 60 min after 10 mcg/kg aqueous GnRH 
analog given subcutaneously [12].
Data were analyzed then using Microsoft Excel 2010. Data 
were presented as mean ± standard deviation or percentage. 
p<0.05 was considered statistically significant. All the statistical 
analyses were done with a 95% confidence interval. Entire 
data were statistically analyzed using Statistical Package for 
the Social Sciences (SPSS ver. 19, IBM Corporation, USA) for 
MS Windows.
RESULTS
A total of 28 children were registered for the study, of which 
23 were girls. The mean age of the presentation of boys was 
5.49±2.76 years while that among the girls was 5.31±2.65 years.
Presenting complaints with which these children were brought 
to the hospital are described in Table 1. Appearance of pubic hair, 
increased penile length, and change in voice were the concerned 
problems in boys, whereas breast development and excess in 
height gain were common in girls (Fig. 1).
Hypothalamic hamartoma (60%) and testicular tumor (40%) 
were the two major etiologies found in boys, whereas in the girls, 
the principle etiology observed was idiopathic.
The first investigation to be conducted was radiological and 
the bone age was advanced in all children. The mean advanced 
bone age was 3.43±2.1 years. The general value of the bone age 
is much higher in boys (4.66±2.21) than in girls (2.20±1.83). MRI 
was done in all boys and in girls <6 years of age with a mean 
age of 5.6±1.2 years. Ultrasonography was done in boys with 
testicular tumor to confirm the diagnosis and in 18 girls of whom, 
9 showed changes of precocity.
Further, several biochemical investigations were also conducted 
as per the protocol. Baseline LH level in 24 children (5 boys) 
showed high values with mean LH levels of 1.4±0.87 mIU/mL in 
boys and 1.305±1.98 mIU/mL in girls. GnRH stimulation test was 
done in 13 children (1 boy) to confirm the diagnosis. About 61.5% 
had results >5 IU/L indicating precocious puberty. Serum estradiol 
Figure 1: Distribution of etiology in girls
Table 1: Complaints of the study population
Presenting complaint Boys (n=5) (%) Girls (n=23) (%)
The appearance of pubic hair 100 30.4
Breast development - 82.6
Increased penile length 100
The appearance of axillary hair 39.1
Enlarged clitoris 4.3
Vaginal bleed 13.04
Excess height gain 69.5
Change in voice 40
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level was done in 14 girls and had mean value of 20.1±17.44 nmol/L 
(the normal range pubertal: >10 nmol/L) while serum testosterone 
in boys had mean value of 359.4±201.08 ng/dL (normal range 
pre-pubertal: 7–20 ng/dL, adult male: 300–1000 ng/dL) which 
were high for the age. Once diagnosed, 18 children (14 girls and 
4 boys) were treated with inj. Leuprolide acetate I.M. monthly 
and the distribution in accordance with the treatment is presented 
in Table 2.
It was observed that the post-treatment height velocity showed 
a declining trend at the end of 19 months of treatment (Table 3) 
as compared to that before the initiation of the treatment. The 
bone age advancement slowed down as well; the LH levels on 
follow-up had a decreasing trend indicating the effectiveness of 
the treatment initiated (Table 4, p<0.05).
In boys, the distribution of mean follow-up z-score of height 
did not differ significantly compared to the mean z-score of height 
at the presentation (p>0.05). In girls, the distribution of mean 
follow-up z-score of height was significantly lower compared 
to the mean z-score of height at the presentation (p<0.05). The 
results thus supported the effectiveness of the intervention given 
(statistically significant in girls and through improved but not 
statistically significant in boys) as described in Table 5.
DISCUSSION
Precocious puberty is relatively uncommon but treatable pediatric 
endocrine disorder. In India, the data regarding precocious puberty 
are not well documented; hence, the frequency, prevalence, 
and exact magnitude of the problem are not known. No data 
were available to provide an estimate of the prevalence rate 
of precocious puberty until 1997 when Herman-Giddens et al. 
reported on the incidence of breast and pubic hair development by 
age and race in 17,000 US girls aged between 3 and 12 years [1].
Most of the studies done around the world were retrospective 
in nature and done over a longer duration. In this regard, a 
prospective observational study was designed with the aim to 
investigate the clinical and endocrinological profile of children 
with precocious puberty during a period of 2 years.
The concern with which children were brought to pediatric 
endocrine outpatient department varied a lot. Among boys, complaint 
of pubic hair growth and genital development was common, four 
boys had increased testicular size and one had a concern of increased 
penile length. Other complaints that gained parental attention were 
changes in the voice (40.0%). In girls, the common presentation was 
breast development (82.6%), followed by axillary hair development 
(39.1%), pubic hair development (30.4%), vaginal bleeding (13.0%), 
and clitoral hypertrophy (4.3%). A total of 12 girls (52.2%) also 
had a history of recent height spurt. Of all children, 8 (28.6%) had 
behavioral issues and seizures as a presenting complaint.
A review of this topic by Walvoord and Mazur concluded that 
CPP may become a risk factor for psychosocial problems, mainly 
in the setting of other risk factors. Authors cautioned against the 
use of medical therapy to avoid presumed negative psychological 
consequences of precocious puberty [13].
In terms of etiology, the data represent that 60.9% of girls had 
CPP with majority of them 71.4% being idiopathic in nature and 
28.6% were diagnosed with hypothalamic hamartoma/pituitary 
adenoma which is consistent with the international data by 
Pescovitz et al., who reported out of 129 patients, of which 73.6% 
were female and 82.9% had CPP, 8.3% had peripheral precocious 
puberty (PPP), and remaining had combined precocious 
puberty [14]. Cisternino et al. reviewed the etiology and age 
incidence in 430 girls over a period of 10 years. A vast majority 
of girls (97.7%) had CPP and only 2.3% had PPP [14].
Table 2: Distribution according to treatment with injectable 
leuprolide acetate
Variable Number of patients
Treatment (n=19) Inj. Leuprolide acetate
Received 18
Not received 1
Dose in males (Mean±SD) (mcg/kg/dose) 190±18.3
Dose in females (Mean±SD) (mcg/kg/dose) 180±14.4
Mean duration (Months) 19±1.41
SD: Standard deviation
Table 3: Height velocity after treatment
Investigations Baseline 
(at diagnosis)
1st follow‑up 
(6 months)
2nd follow‑up 
(12 months)
3rd follow‑up 
(after 18–20 months)
p value
Height (cm) 119 126 130 133 <0.05
p-values calculated by paired t-test. p<0.05 is considered statistically significant
Table 4: Stimulated LH levels on follow‑up
Investigations Post‑stimulation at 
presentation
3 h after leuprolide on the 
1st follow‑up
3 h after leuprolide on 
the 2nd follow‑up
p value
LH 3.38 1.84 1.94 <0.05
p-values calculated by paired t-test. p<0.05 is considered to be statistically significant, LH: Luteinizing hormone
Table 5: Sex‑specific comparison of mean height Z score at presentation and at follow‑up
Parameters Boys (n=5) Girls (n=23)
Mean±SD Presentation Follow‑up p value Presentation Follow‑up p value
Z score height 1.76±1.31 1.93±2.72 0.826NS 1.10±1.50 −4.82±11.1 0.032*
p-values calculated by paired t-test. p<0.05 is considered to be statistically significant. SD: Standard deviation
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Bajpai and Menon reviewed 140 cases of precocious puberty 
at a tertiary care center in Indian children and reported that 
majorities were female, 67% had CPP, 11.5% had PPP, and 
remaining had normal benign variants. The most common cause 
of precocious puberty in boys was secondary to adrenal causes 
while in girls, it was due to ovarian cysts [6]. In the current study, 
remaining 39.1% of girls had a peripheral cause for precocious 
puberty constituting ovarian tumor (11.1%), adrenal adenoma 
(11.1%), and benign thelarche (55.5%)/thelarche variant (11.1%). 
In boys, hypothalamic hamartoma was the cause of (60.0%) 
followed by Leydig cell tumors (40.0%). This could be attributed 
to the present tertiary care center, which is a referral center with 
pediatric endocrine facilities, and hence, an increased number of 
referrals were coming from the peripheries.
In the past decade, new gonadotropin assays with better 
sensitivity and specificity have been developed, which make 
them particularly useful to study the ontogenesis of LH secretion 
in normal and abnormal puberty [15]. The present results 
demonstrate that both basal and GnRH-stimulated levels of 
LH exhibit high specificity for the diagnosis of gonadotropin-
dependent precocious puberty. The present study had mean 
baseline LH levels of 1.2 IU/L with post-stimulation levels 
significantly rising to mean 16.38 IU/L at the end of 60 min. 
Treatment with GnRH agonists resulted in the regression or 
stabilization of pubertal symptoms, decrease in the growth 
velocity, bone age advancement, and improved adult height [16].
This study had similar results on follow-up with the patients 
after a mean period of 18 months post-treatment with GnRH 
analog. There was a decrease in high velocity and bone age 
advancement and stabilization in pubertal symptoms. The LH 
levels documented on follow-up showed a decreasing trend 
as well. Significant benefit was observed in clinical as well as 
psychosocial domains. A major limitation of the present study 
was the small range of sample enlisted in the study population. 
A larger study sample would have validated the outcome of the 
study more efficiently.
CONCLUSIONS
An increasing trend of precocious puberty and its adverse effect 
on final height and psychological profile of patients mandates the 
need for early referral and diagnosis and appropriate management. 
The etiologies are heterogeneous, and treatment and prognosis 
differ according to the etiology. Detailed evaluation including 
radiological and biochemical tests is required. It is important to 
correct the underlying pathology based on the exact diagnosis. 
The medical treatment with monthly inj. Leuprolide acetate has 
shown a decline in a rapid progression of symptoms of precocious 
puberty and has improvement of height outcomes as well as in 
follow-up hormone levels.
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